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Introduction
Trisomy 12 represents the third most frequent chromoso-
mal aberration in chronic lymphocytic leukemia (CLL) (15-
20% of cases) and often (approx. 60% of cases) occurs as the
sole cytogenetic lesion.1,2 Within the hierarchical model of
genetic subgroups commonly used in clinical practice, +12 as
single aberration confers an intermediate prognostic risk,
with a median time to progression of 33 months and a medi-
an overall survival (OS) of 114 months.1
The NOTCH1 gene has been shown to have an essential
biological role in hematopoiesis.3 Following the pivotal study
that identified NOTCH1 mutations in CLL and provided ini-
tial evidence on the unfavorable clinical outcome associated
with NOTCH1 alterations,4 two independent studies of the
CLL coding genome have recently identified activating muta-
tions of the NOTCH1 gene in approximately 10% of CLL at
diagnosis.5,6 The prevalence of NOTCH1 mutations increases
with disease aggressiveness.5 At diagnosis, NOTCH1 muta-
tions show an adverse impact on outcome, confirmed in at
least four series,4-7 and act independently of other clinico-bio-
logical features, including TP53 disruption.7 Among CLL cyto-
genetic subgroups, NOTCH1 mutations are distributed in a
mutually exclusive fashion with TP53 disruption and are
enriched in CLL carrying +12, where they recur in approxi-
mately 25% of patients.7
Based on the emerging association between NOTCH1
alterations and +12, we investigated NOTCH1mutations in a
series of untreated +12 CLL. We observed that in these
patients, NOTCH1 mutations: i) cluster within cases with no
additional cytogenetic abnormalities; ii) induce a particular
transcriptional profile; and iii) refine outcome prediction.
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Trisomy 12, the third most frequent chromosomal aberration
in chronic lymphocytic leukemia (CLL), confers an interme-
diate prognosis. In our cohort of 104 untreated patients car-
rying +12, NOTCH1mutations occurred in 24% of cases and
were associated to unmutated IGHV genes (P=0.003) and
+12 as a sole cytogenetic abnormality (P=0.008). NOTCH1
mutations in +12 CLL associated with an approximately 2.4
fold increase in the risk of death, a significant shortening of
survival (P<0.01) and proved to be an independent predictor
of survival in multivariate analysis. Analogous to +12 CLL
with TP53 disruption or del(11q), NOTCH1mutations in +12
CLL conferred a significantly worse survival compared to
that of +12 CLL with del(13q) or +12 only. The overrepresen-
tation of cell cycle/proliferation related genes of +12 CLL
with NOTCH1 mutations suggests the biological contribu-
tion of NOTCH1 mutations to determine a poor outcome.
NOTCH1 mutations refine the intermediate prognosis of
+12 CLL.
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This multicenter study evaluated 104 patients carrying +12: 54
were males and 50 females, with a median age of 65 years
(interquartile range 56-72). All cases satisfied the IWCLL diagnostic
criteria for CLL8 and were selected on the basis of: i) untreated dis-
ease; ii) availability of biological material; and iii) presence of +12,
independent of additional chromosomal abnormalities.
Patients gave their informed consent to blood collection and bio-
logical analyses, in agreement with the Declaration of Helsinki.
The study was approved by the Ethical Committee of Policlinico
Umberto I, “La Sapienza” University of Rome (n. 2182/16.06.2011)
and of the Ospedale Maggiore della Carità, Novara, northern Italy,
associated with the Amedeo Avogadro University of Eastern
Piedmont (protocol code 59/CE; study n. CE 8/11).
Lymphocyte morphology, immunophenotype, FISH analysis,
IGHV and TP53 sequencing were performed as previously
described.9
Mutation analysis of NOTCH1
The NOTCH1 (exon 34; RefSeq NM_017617.2) mutation
hotspot previously identified in CLL7 was analyzed by direct
sequencing of genomic DNA extracted from blood mononuclear
cells. Purified amplicons were subjected to conventional DNA
Sanger sequencing using the ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems, CA, USA). The presence of NOTCH1
c.7544_7545delCT alleles was also investigated by ARMS PCR.
Further details are reported in the Online Supplementary Design and
Methods.
Statistical analysis 
Overall survival (OS) was measured from the date of initial pres-
entation to the date of death (event) or last follow up (censoring).
Survival analysis was performed by the Kaplan-Meier method.
Further details are reported in the Online Supplementary Design and
Methods.
Gene expression profile analysis
For oligonucleotide array analysis, the HGU133 Plus 2.0 gene
chips (Affymetrix, Santa Clara, CA, USA) were used. Sample
preparation and microarray processing were performed as previ-
ously described.10 Further details are reported in the Online
Supplementary Design and Methods.
Results and Discussion
Frequency and distribution of NOTCH1 mutations 
in +12 CLL 
NOTCH1mutations occurred in 25 of the 104 untreated
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Table 1A. Characteristics of CLL patients harboring +12 according to the NOTCH1 mutation status.
Characteristicsa All NOTCH1 NOTCH1
(n=104) wild type mutated
(n=79) (n=25)
nb % nb % n % P
Age >65 years 52 50 40 51 12 48 0.819
Male 54 52 43 54 11 44 0.363
Binet B-C 37 36 26 33 11 44 0.313
IGHV identity ≥98% 60 58 39 50 21 84 0.003
13q14 deletion 19 18 19 24 0 0 0.006
Trisomy 12 only 73 70 51 65 23 92 0.008
11q22-q23 deletion 8 8 6 8 2 8 1.000
17p13 deletion 5 5 4 5 1 4 1.000
TP53mutations 4 4 2 3 2 8 0.243
TP53 disruption 8 8 5 6 3 12 0.395
aIGHV: immunoglobulin heavy variable gene; bIGHV: rearrangement was not available for one NOTCH1 wild-type patient.
Table 1B. Univariate and multivariate analysis for overall survival in CLL patients harboring +12a.
OS (years) Univariate analysis Multivariate analysis
Characteristics Events Total Median LCI UCI HR LCI UCI P HR LCI UCI P
Age ≤65 years 15 51 15.6 10.4 20.7 - - - - - -
Age >65 years 21 52 6.7 3.6 9.9 2.92 1.44 5.92 0.003 6.03 2.60 13.95 <0.001
Binet A 19 69 15.6 9.7 21.4 - - - - - -
Binet B-C 17 36 7.8 5.5 10.0 2.47 1.26 4.82 0.008 2.40 1.17 4.89 0.016
IGHV identity <98% 12 43 15.6 9.2 21.9 - - - - - -
IGHV identity ≥98% 23 59 11.1 7.6 14.6 2.35 1.07 5.12 0.032 2.14 0.90 5.11 0.085
NOTCH1 wild-type 21 78 13.0 8.9 17.1 - - - - - -
NOTCH1mutations 15 25 7.8 1.2 14.3 2.46 1.26 4.81 0.008 3.04 1.39 6.64 0.005
TP53 wild-type 30 95 13.0 10.5 15.5 - - - - - -
TP53 disruption 6 8 5.6 3.0 8.3 3.18 1.29 7.80 0.011 3.46 1.38 8.70 0.008
aOS: overall survival; HR: hazard ratio; LCI: 95% lower confidence interval; UCI: 95% upper confidence interval; IGHV: immunoglobulin heavy variable gene.
CLL with +12 investigated (24%) (Table 1A), were repre-
sented in all cases by frameshift deletions, including the
c.7544_7545delCT in 22 of 25 (88%) cases, and preferen-
tially associated with use of unmutated IGHV genes
(84%, P=0.003). NOTCH1 mutations occurred independ-
ent of gender, thus suggesting that NOTCH1 mutations
might be an important marker of unfavorable prognosis in
both male and female CLL patients.
Trisomy 12 occurred as an isolated chromosomal abnor-
mality in 73 of 104 (70%) cases, while it was associated to
other cytogenetic abnormalities in 31 of 104 (30%) cases
(Figure 1A). Mutual information analysis revealed a cluster-
ing of NOTCH1mutations among CLL harboring +12 as a
sole abnormality (22 of 73, 30%) compared to patients har-
boring +12 in addition to other cytogenetic lesions (2 of 31,
6%) (I=0.027; P=0.008) (Figure 1A). Consistently, +12 CLL
harboring NOTCH1mutations carried deletion 13q14 only
exceptionally (0 of 19). Consistent with pivotal observa-
tions,5,7 also in +12 CLL, NOTCH1mutations distributed in
a mutually exclusive fashion with deletions of 17p13 and
11q22-q23 (Figure 1A).
This extended cohort corroborates the high prevalence
of NOTCH1 mutations in +12 CLL, where the overall fre-
quency of NOTCH1mutations in +12 patients consistent-
ly ranges from 24.5 to 28.6%.7,11 Furthermore, +12 patients
harboring NOTCH1 mutations prevalently belong to
aggressive cases, i.e. cases with an unmutated IGHV gene
status, in line with recent findings,7,11 and expression of
CD38 (NOTCH1 mutated/CD38 positive, n=20 of 25
(80.0%) vs. NOTCH1 wild-type/CD38 positive, n=39 of
77 (50.6%) (P=0.010).
At variance, no difference emerged in the distribution of
ZAP-70 positivity (NOTCH1 mutated/ZAP-70 positive,
n=15 of 24 (62.5%) vs. NOTCH1 wild-type/ ZAP-70 posi-
tive, n=34 of 77 (44.2%) (P=0.116). 
Finally, the analysis of this specific cohort of patients
showed an enrichment of NOTCH1mutations in CLL har-
boring+12 as sole cytogenetic abnormality.
NOTCH1 mutations in +12 CLL
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Figure 1. (A) Distribution of NOTCH1 mutations among genetic subgroups of +12 CLL. (B) Overall survival according to NOTCH1 mutation
status in +12 CLL. (C) Hierarchical stratification of overall survival according to genetic lesions in +12 CLL. (D) Comparison between NOTCH1
mutated and NOTCH1 wt CLL samples. Relative levels of gene expression are depicted with a color scale: red represents the highest level
of expression and blue represents the lowest level. The table reports the functional annotation analysis, performed using the DAVID data-
base, of differentially expressed genes between NOTCH1mutated and NOTCH1 wt CLL. The biological processes reported are ordered accord-
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NOTCH1 mutations and overall survival in +12 CLL
After a median follow up of seven years, 36 of 103
evaluable patients had died, for a median OS of 11.6 years
(95% CI: 10.4-12.7). By univariate analysis, the crude
impact of NOTCH1mutations on survival in +12 CLL was
an approximately 2.4 fold increase in the hazard of death
(HR: 2.46; 95% CI: 1.26-4.81) and a significant shortening
of OS (P<0.01) (Table 1B; Figure 1B). Other variables asso-
ciated with shorter OS were age, Binet stage, IGHVmuta-
tion status and TP53 disruption.
Multivariate analysis selected NOTCH1mutations as an
independent risk factor of OS (HR: 3.04; 95% CI: 1.39-
6.64; P<0.01), after adjusting for age (> vs. ≤65 years), Binet
stage (B-C vs. A), IGHV mutation status and TP53 disrup-
tion by mutation and/or deletion. NOTCH1 mutations,
13q14 deletion, 11q22-q23 deletion and TP53 status were
used to build a hierarchical model of genetic subgroups to
predict OS in CLL with +12. The outcome of +12 CLL
with NOTCH1 mutations was poor, similar to cases with
+12 and TP53 disruption or 11q22-q23 deletion and signif-
icantly worse than patients with +12 as an isolated abnor-
mality or plus 13q14 deletion (Figure 1C).
NOTCH1 mutations represent, therefore, an independ-
ent adverse prognostic factor of OS among +12 CLL, pro-
viding a new genetic prognostic stratification of patients
with this intermediate risk marker.
Gene expression profiling of +12 CLL
with NOTCH1 mutations
To understand whether NOTCH1 mutations induced a
distinctive transcriptional profile in +12 CLL, we com-
pared 7 NOTCH1 mutated vs. 7 NOTCH1 wild-type
cases in a cohort of patients carrying +12 (Online
Supplementary Table S1).
This analysis showed that NOTCH1 mutated cases
formed a tight clustering (Figure 1D), with 2 patients
incorrectly placed. Of these, one later developed a TP53
mutation and a myelodysplastic syndrome (CLL_00248,
Online Supplementary Table S1).
Sixty-five differentially expressed genes (Online
Supplementary Table S2) were selected, the majority being
upmodulated in NOTCH1mutated samples. DAVID func-
tional annotation analysis highlighted an overrepresenta-
tion of cell cycle related genes, indicating that NOTCH1
mutations induce a proliferative advantage that might
explain the clinically aggressive behavior (Figure 1D). We
also observed significantly higher levels of IgM expression
in NOTCH1 mutated cases. It is known that IgM expres-
sion is higher in cells with increased ability to respond to
external stimuli,12,13 indicating that the NOTCH1 mutated
clone might survive and expand also thanks to these inter-
actions. Intriguingly, approximately 30% of the upregulat-
ed transcripts were located on chromosome 12. This
might be due to the fact that +12 was present as a single
alteration in all NOTCH1 mutated cases, whereas in the
NOTCH1 wild-type subgroup the scenario was more
complex, with 3 cases displaying only +12 and 4 cases one
or more additional chromosomal aberrations.
Among the transcripts previously reported to be associ-
ated with a +12 signature, we confirmed the upregulation
of ANAPC5, GLIPR1, TIMELESS and SLC2A6.14,15
In summary, this study highlights that NOTCH1 muta-
tions in +12 CLL: i) preferentially cluster with cases harbor-
ing +12 as sole genetic abnormality; ii) account for 24% of
cases and are more frequently detected in cases with unfa-
vorable biological markers; iii) associate with a particular
gene expression profile; iv) predict a poor outcome, strati-
fying +12 CLL in two distinct subgroups; and v) are not
associated with TP53 disruption or 11q deletion, thus mak-
ing them even more useful in a genetic hierarchical prog-
nostic model, given their mutual exclusivity. This observa-
tion sheds light on the heterogeneous clinical course of +12
CLL patients and allows us to refine the intermediate prog-
nostic risk of this chromosomal lesion. The transcriptional
profile characterized by an overrepresentation of genes
involved in cell cycle and proliferation suggests the poten-
tial biological contribution of NOTCH1mutations in deter-
mining the aggressive behavior of the disease.
Authorship and Disclosures
The information provided by the authors about contributions from
persons listed as authors and in acknowledgments is available with
the full text of this paper at www.haematologica.org.
Financial and other disclosures provided by the authors using the
ICMJE (www.icmje.org) Uniform Format for Disclosure of
Competing Interests are also available at www.haematologica.org.
I. Del giudice et al.
440 haematologica | 2012; 97(3)
References
1. Döhner H, Stilgenbauer S, Benner A,
Leupolt E, Kröber A, Bullinger L, et al.
Genomic aberrations and survival in chron-
ic lymphocytic leukemia. N Engl J Med.
2000;343(26):1910-6.
2. Matutes E, Oscier D, Garcia-Marco J, Ellis J,
Copplestone A, Gillingham R, et al.
Trisomy 12 defines a group of CLL with
atypical morphology: correlation between
cytogenetic, clinical and laboratory features
in 544 patients. Br J Haematol. 1996;92(2):
382-8.
3. Milner LA, Bigas A. Notch as a mediator of
cell fate determination in hematopoiesis:
evidence and speculation. Blood. 1999;93
(8):2431-48.
4. Sportoletti P, Baldoni S, Cavalli L, Del Papa
B, Bonifacio E, Ciurnelli R, et al. NOTCH1
PEST domain mutation is an adverse prog-
nostic factor in B-CLL. Br J Haematol.
2010;151(4):404-6.
5. Fabbri G, Rasi S, Rossi D, Trifonov V,
Khiabanian H, Ma J, et al. Analysis of the
chronic lymphocytic leukemia coding
genome: role of NOTCH1 mutational acti-
vation. J Exp Med. 2011;208(7):1389-401.
6. Puente XS, Pinyol M, Quesada V, Conde L,
Ordóñez GR, Villamor N, et al. Whole-
genome sequencing identifies recurrent
mutations in  chronic lymphocytic
leukaemia. Nature. 2011;475(7354):101-5.
7. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio
M, Forconi F, Marasca R, et al. Mutations of
NOTCH1 are an independent predictor of
survival in chronic lymphocytic leukemia.
Blood. 2012;119(2):521-9.
8. Hallek M, Cheson BD, Catovsky D,
Caligaris-Cappio F, Dighiero G, Döhner H,
et al. International Workshop on Chronic
Lymphocytic Leukemia. Guidelines for the
diagnosis and treatment of chronic lym-
phocytic leukemia: a report from the
International Workshop on Chronic
Lymphocytic Leukemia updating the
National Cancer Institute-Working Group
1996 guidelines. Blood. 2008;112(13):5259-
69.
9. Del Giudice I, Mauro FR, De Propris MS,
Santangelo S, Marinelli M, Peragine N, et al.
White blood cell count at diagnosis and
immunoglobulin variable region gene
mutations are independent predictors of
treatment-free survival in young patients
with stage A chronic lymphocytic
leukemia. Haematologica. 2011;96(4):626-
30.
10. Chiaretti S, Tavolaro S, Marinelli M,
Messina M, Del Giudice I, Mauro FR, et al.
Evaluation of TP53 mutations with the
AmpliChip p53 research test in chronic
lymphocytic leukemia: correlation with
clinical outcome and gene expression pro-
filing. Genes Chromosomes Cancer.
2011;50(4):263-74.
11. Balatti V, Bottoni A, Palamarchuk A, Alder
H, Rassenti LZ, Kipps TJ, et al. NOTCH1
mutations in CLL associated with trisomy
12. Blood. 2012;119(2):329-31.
12. Mockridge CI, Potter KN, Wheatley I,
Neville LA, Packham G, Stevenson FK.
Reversible anergy of sIgM-mediated signal-
ing in the two subsets of CLL defined by
VH-gene mutational status. Blood.
2007;109(10):4424-31.
13. Guarini A, Chiaretti S, Tavolaro S, Maggio
R, Peragine N, Citarella F, et al. BCR ligation
induced by IgM stimulation results in gene
expression and functional changes only in
IgV H unmutated chronic lymphocytic
leukemia (CLL) cells. Blood. 2008;112(3):
782-92.
14. Haslinger C, Schweifer N, Stilgenbauer S,
Döhner H, Lichter P, Kraut N, et al.
Microarray gene expression profiling of B-
cell chronic lymphocytic leukemia sub-
groups defined by genomic aberrations and
VH mutation status. J Clin Oncol. 2004;
22(19):3937-49.
15. Porpaczy E, Bilban M, Heinze G, Gruber
M, Vanura K, Schwarzinger I, et al. Gene
expression signature of chronic lymphocyt-
ic leukaemia with Trisomy 12. Eur J Clin
Invest. 2009;39(7):568-75.
NOTCH1 mutations in +12 CLL
haematologica | 2012; 97(3) 441
